Pacifico Biolabs

High-Level Overview

Pacifico Biolabs is a Berlin-based biotechnology company founded in 2022 that develops sustainable meat alternatives, primarily seafood and other meats like chicken, pork, and fish, using mycelium fermentation technology.[1][2][5] It produces Viando, a line of mycelium-based "mycomeat" products designed for B2B customers in the food industry, offering realistic taste, texture, and nutrition while requiring up to 99% less land, 90% less water, and 90% fewer CO2 emissions than traditional animal meat.[5] The company serves food manufacturers by integrating directly into existing supply chains and recipes, solving the problem of unsustainable seafood and meat production amid rising global demand and environmental pressures.[1][2][5] With $3.3M raised in a convertible note round and public funding, Pacifico is in early scaling stages, focusing on European market launch post-regulatory approval.[1][2][3]

Origin Story

Pacifico Biolabs was co-founded in 2022 by Zac Austin (CEO, former McKinsey strategy consultant in London and British government COVID taskforce member) and Washington Logroño (biotechnology graduate who migrated from Ecuador to Europe).[2] The idea emerged from their collaboration on fermentation innovations for fragmented seafood products like white fish fillets, where traditional methods fall short.[2] Emerging from stealth in early 2024 with seed funding, the company quickly gained traction through public grants for mycelium-based vegan meat alternatives and venture backing, positioning it as a leader in biomass-fermented seafood.[2][3]

Core Differentiators

• Mycelium Fermentation for Whole-Muscle Structures: Cultivates multiple microorganisms, including mycelium (fungi roots), to create nutritious biomass with realistic flavor, texture, and nutrition for products like white fish fillets, chicken, pork, and fish—unlike precision fermentation suited only for raw ingredients.[1][2][5]
• Sustainability and Efficiency: Uses food production side streams to cut waste; requires drastically fewer resources (99% less land, 90% less water/CO2) while being healthier and lower-cost than competitors.[4][5]
• B2B Seamless Integration: Viando products drop into existing meat processing equipment, recipes, and value chains without redesign, enabling blended or fully plant-based offerings for food manufacturers.[5]
• Early-Stage Momentum: Backed by top VCs and angels; focuses on scalable bioreactors over capital-intensive infrastructure, with competitors like Marinexcell (stem-cell shellfish) and Sea2Cell (cultivated fish) highlighting its unique fungal approach.[1][2]

Role in the Broader Tech Landscape

Pacifico Biolabs rides the alternative protein wave, targeting seafood—a sector with $808M in VC funding across 56 deals in 2023 amid overfishing, climate impacts, and 20%+ annual demand growth.[2] Its timing aligns with EU regulatory progress for novel foods and mycelium's centuries-old safety profile, enabling faster market entry than cell-cultured meats.[2][5] Market forces like resource scarcity and consumer shifts toward sustainable, nutritious options favor its low-cost, high-yield model, influencing the ecosystem by proving fermentation can disrupt legacy meat supply chains without overhauls.[1][5] As a deep tech player, it accelerates biotech's role in food security, competing with plant-based and cultivated proteins while bridging to mainstream adoption.[1][2][4]

Quick Take & Future Outlook

Pacifico is poised to launch Viando Chicken in Europe soon, with pork and fish following, leveraging its pre-seed momentum to scale bioreactors and secure approvals.[2][5] Trends like precision ag-tech advancements, rising alt-seafood investments, and corporate sustainability mandates will propel growth, potentially expanding to global B2B partnerships.[2][5] Its influence may evolve from niche innovator to supply chain staple, redefining meat companies by swapping animals for fungi—delivering the sustainable, drop-in alternatives the food industry craves.[5]